Phibro Animal Health (PAHC) Stock: Buy, Sell, or Hold?
PAHC - Phibro Animal Health Corporation Class A
$39.81
0.56 (1.43%)
▲
5d:
+4.82%
30d:
+16.74%
90d:
+16.97%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 04, 2026
12d
Get Alerted When PAHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PAHC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PAHC shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$59.38
Based on 6.5% avg growth
INTRINSIC VALUE TODAY
$36.87
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PAHC is currently trading at $39.81, which is considered extended relative to its 30-day fair value range of $34.87 to $38.30. The stock's valuation (Forward PE: 11.9) is in line with its historical norms (13.0). Remarkably, the market is currently pricing in an annual earnings decline of 3.0% over the next few years. This pessimistic expectation contrasts with the company's recent 24.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, PAHC is in a strong uptrend. The price is approaching resistance at $40.87. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PAHC scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $47.00 (+18.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PAHC is in a strong uptrend. The price is approaching resistance at $40.87. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: PAHC scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $47.00 (+18.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$34.87 -
$38.30
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
40.4%
Protect Your Profits
Holding PAHC? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($47.00)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$34.87 -
$38.30
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$2.51
(6.3%)
Support & Resistance Levels
Support Level
$36.53
Resistance Level
$40.87
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.90
Wall Street Target
$47.00
(+18.1%)
Revenue Growth (YoY)
4.8%
Earnings Growth (YoY)
24.6%
Profit Margin
6.6%
Valuation Discount vs History
-3.0% cheaper
PE vs Historical
11.9 vs 13.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.0%
(market-implied from PE analysis)
1-Year Target
$38.62
(-3%)
2-Year Target
$37.46
(-6%)
3-Year Target
$36.33
(-9%)
3-Yr Target (if PE normalizes)
(PE: 12→13)
$39.68
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 8.9%)
$85.65
(+115%)
Base:
(SPY PE: 11.9, Growth: 8.9%)
$51.34
(+29%)
Bear:
(PE: 10.1, Growth: 8.9%)
$43.64
(+10%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 16.17 | Current EPS (TTM): $2.40
Bull Case
$59.47
(+52%)
Analyst growth 39.3%, PE expands to 17.8
Base Case
$54.06
(+38%)
Market implied 39.3%, PE stable at 16.2
Bear Case
$26.38
(-33%)
Severe decline -20.0%, PE contracts to 13.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.9 to 13.0
Stabilization Target:
$43.47
(+9.2%)
PE Expansion Potential:
+9.2%
Share & Embed Analysis
Last updated: October 22, 2026 5:44 PM ET
Data refreshes hourly during market hours. Next update: 6:44 PM
Data refreshes hourly during market hours. Next update: 6:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PAHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |
Advanced PAHC Option Strategies
Professional options setups generated by AI based on today's PAHC price and gamma walls.
